Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420406 | 0.89 | GNAI3 (0.54) | ACKR3SIGMAR1ALDH1A1SMN1; SMN2GNAI3 | |
| SCHEMBL10274562 | 0.89 | MTNR1A (0.49) | ACKR3MTNR1AMTNR1BL3MBTL1SMN1; SMN2 | |
| SCHEMBL10265277 | 0.85 | SIGMAR1 (0.49) | ACKR3MTNR1AMTNR1BSIGMAR1ALDH1A1 | |
| SCHEMBL5988081 | 0.84 | — | — | |
| SCHEMBL14199968 | 0.84 | SMN1; SMN2 (0.56) | MTNR1AMTNR1BALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL20581686 | 0.84 | SMN1; SMN2 (0.56) | MTNR1AMTNR1BALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL15279721 | 0.84 | ACKR3 (0.52) | ACKR3SIGMAR1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL21730556 | 0.84 | EPHX1 (0.50) | MTNR1AMTNR1BALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13621162 | 0.84 | ALDH1A1 (0.62) | ACKR3SIGMAR1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13116786 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-9834565-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-9527864-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-0707586-B1 | POSITIVE INOTROPIC AND LUSITROPIC PYRROLOQUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | ACKR3 3098/4885MTNR1A 4317/4885MTNR1B 3973/4885 |
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | ACKR3 1263/4885MTNR1A 4360/4885MTNR1B 4178/4885 |
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ACKR3 840/4885MTNR1A 2427/4885MTNR1B 1774/4885 |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | ACKR3 2231/4885MTNR1A 3828/4885MTNR1B 3400/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | ACKR3 975/4885MTNR1A 3363/4885MTNR1B 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.